Oyster Point Pharma, Inc
700 Alexander Park Drive Suite 301
Princeton, NJ 08540
About Oyster Point Pharma, Inc
Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. The parasympathetic nervous system (PNS) is part of the involuntary nervous system responsible for regulating homeostasis, the “rest and digest” system, and is an important pathway for basal tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production in patients with Dry Eye Disease (DED).
Oyster Point Pharma, named after the Oyster Point waterfront on San Francisco Bay, was founded in 2015 and is headquartered in Princeton, New Jersey.
6 articles with Oyster Point Pharma, Inc
Oyster Point Pharma Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Disease
Multicenter, Randomized ONSET-2 Study Will Evaluate OC-01 as Novel Option for Common Eye Condition
Oyster Point Pharma to Present at the 2019 ASCRS•ASOA Annual Meeting and at the Ophthalmology Innovation Summit (OIS) Meeting
Oyster Point Pharma, Inc. announced multiple data presentations of the company’s product candidates at the 2019 American Society for Cataract and Refractive Surgery Annual Meeting and at the Ophthalmology Innovation Summit meeting, taking place May 2-7 in San Diego.
Jeffrey Nau, Ph.D., M.M.S., President and CEO, is scheduled to present a corporate overview at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11th, 2019 at 5:00 p.m. ET at the Boston Marriott Copley Place.
Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Disease
Lead Clinical Candidate to Advance to Phase 3 Clinical Development
The company’s two lead product candidates are OC-01 and OC-02, which are delivered by way of an ocular surface-sparing nasal spray that stimulates the trigeminal parasympathetic pathway to induce natural tear film production.
Jeffrey Nau, Ph.D., M.M.S, President and CEO, is scheduled to present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27th, 2019 at 1:30pm EST in New York.